What if chemotherapy could be targeted to only attack a patient's tumor?
That's the promise of Antibody-Drug Conjugates.
In this clip from our latest Webinar, Jason Sager, MD, explains what antibody-drug conjugates are and what they mean for cancer patients.
We discuss how patients get access and what they can expect in treatment.
Many ADCs have been approved for different types of cancer and many are available in clinical trials.